Notice of the Annual General Meeting of Diagnostyka S.A.

Date: 30 April 2025

Subject: Notice of the Annual General Meeting of Diagnostyka S.A.

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Pursuant to Art. 399.1 of the Commercial Companies Code, the Management Board of Diagnostyka S.A. has resolved to convene the Annual General Meeting of the Company, to be held at the Cogiteon Małopolska Science Centre, ul. Stefana Steca 1, Kraków, at 12.00 a.m. on 28 May 2025.

The following agenda has been proposed for the General Meeting:

1. Opening of the Annual General Meeting.
2. Appointment of the Chair of the Annual General Meeting.
3. Confirmation that the Annual General Meeting has been duly convened and has the capacity to pass resolutions.
4. Adoption of the agenda.
5. Consideration of the reports prepared by the Company’s governing bodies, the financial statements of the Company and the consolidated financial statements of the Group for 2024.
6. Voting on a resolution to approve the financial statements of the Company for 2024.
7. Voting on a resolution to approve the consolidated financial statements of the Diagnostyka Group for 2024.
8. Voting on a resolution to approve the Directors’ Report on the operations of the Diagnostyka Group for the financial year 2024 (including the report on the operations of the Company in that period and sustainable reporting of the Diagnostyka Group for the financial year 2024).
9. Voting on a resolution on the allocation of the Company’s profit for 2024.
10. Voting on a resolution to grant discharge from liability to Jakub Swadźba for his activities as President of the Management Board in the period from 1 January to 31 December 2024.
11. Voting on a resolution to grant discharge from liability to Dariusz Zowczak for his activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
12. Voting on a resolution to grant discharge from liability to Marta Rogalska-Kupiec for her activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
13. Voting on a resolution to grant discharge from liability to Paweł Chytła for his activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
14. Voting on a resolution to grant discharge from liability to Michał Kantor for his activities as Vice President of the Management Board in the period from 1 January to 19 May 2024.
15. Voting on a resolution to grant discharge from liability to Artur Olender for his activities as Chair of the Supervisory Board in the period from 1 January to 31 December 2024.
16. Voting on a resolution to grant discharge from liability to Jacek Prusek for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
17. Voting on a resolution to grant discharge from liability to Grzegorz Głownia for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
18. Voting on a resolution to grant discharge from liability to Marcin Fryda for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
19. Voting on a resolution to grant discharge from liability to Paweł Malicki for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
20. Voting on a resolution to grant discharge from liability to Matthew Strassberg for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
21. Voting on a resolution to grant discharge from liability to Aniela Hejnowska for her activities as Member of the Supervisory Board in the period from 1 October to 31 December 2024.
22. Voting on a resolution to approve the annual report of the Company’s Supervisory Board for 2024.
23. Voting on a resolution to grant discharge from liability to Anna Pietrykowska for her activities as President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
24. Voting on a resolution to grant discharge from liability to Joanna Brąszkiewicz for her activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
25. Voting on a resolution to grant discharge from liability to Patryk Preis for his activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
26. Voting on a resolution to grant discharge from liability to Andrzej Drobny for his activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
27. Voting on a resolution to grant discharge from liability to Jakub Strzelczyk for his activities as President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 8 April 2024.
28. Voting on a resolution to grant discharge from liability to Przemysław Kulas for his activities as Vice President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 29 November 2024.
29. Voting on a resolution to grant discharge from liability to Marek Kubicki for his activities as Vice President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 29 November 2024.
30. Closing of the meeting.

Attached to this Report is the notice of the Annual General Meeting, made pursuant to Art. 402.2 of the Commercial Companies Code, along with the draft resolutions of the General Meeting to be voted on and resolutions of the Supervisory Board to be discussed at the General Meeting. Other documents are available in the ‘Periodic reports’ section on the Company’s website at www.grupadiagnostyka.pl/dla-inwestorow/.

Legal basis: Section 19.1.1 and 19.1.2 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state, dated 29 March 2018.

Signatures of authorised representatives:

Jakub Swadźba – President of the Management Board

Paweł Chytła – Vice President of the Management Board